|
|
|
|
LEADER |
01000cam a2200265 4500 |
001 |
024207977 |
003 |
DE-627 |
005 |
20240416011052.0 |
007 |
tu |
008 |
880309s1987 gw ||||| 00| ||eng c |
010 |
|
|
|a 87028770
|
015 |
|
|
|a 88,N03,0390
|2 dnb
|
015 |
|
|
|a 88,A11,0591
|2 dnb
|
016 |
7 |
|
|a 880089067
|2 DE-101
|
020 |
|
|
|a 3540172777
|9 3-540-17277-7
|
020 |
|
|
|a 0387172777
|9 0-387-17277-7
|
035 |
|
|
|a (DE-627)024207977
|
035 |
|
|
|a (DE-576)017579473
|
035 |
|
|
|a (DE-599)GBV024207977
|
035 |
|
|
|a (OCoLC)16950357
|
035 |
|
|
|a (OCoLC)16950357
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
044 |
|
|
|c XA-DE
|c XD-US
|c XA-GB
|c XB-JP
|
050 |
|
0 |
|a RC632.H87
|
060 |
|
0 |
|a QU 85 D794
|
082 |
0 |
|
|a 616.3/997061
|q LOC
|2 19
|
084 |
|
|
|a 33
|2 sdnb
|
084 |
|
|
|a 44.38
|2 bkl
|
245 |
1 |
0 |
|a Drugs affecting lipid metabolism
|b with 132 figures
|c [Drugs Affecting Lipid Metabolism Meeting]. Ed. by R. Paoletti ...
|
264 |
|
1 |
|a Berlin
|a Heidelberg
|a New York
|a London
|a Paris
|a Tokyo
|b Springer
|c 1987
|
300 |
|
|
|a XVI, 451 S.
|b Ill., graph. Darst.
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
490 |
0 |
|
|a Proceedings in life sciences
|
500 |
|
|
|a Literaturangaben
|
583 |
1 |
|
|a Archivierung prüfen
|c 20200919
|f DE-640
|z 3
|2 pdager
|
583 |
1 |
|
|a Archivierung/Langzeitarchivierung gewährleistet
|f PEBW
|x XA-DE-BW
|2 pdager
|5 DE-31
|
583 |
1 |
|
|a Archivierung prüfen
|c 20240324
|f DE-4165
|z 3
|2 pdager
|
650 |
|
0 |
|a Hyperlipidemia
|x Chemotherapy
|
650 |
|
0 |
|a Antilipemic agents
|x Testing
|
650 |
|
0 |
|a Blood lipoproteins
|x Metabolism
|
650 |
|
0 |
|a Blood cholesterol
|x Metabolism
|
650 |
|
0 |
|a Lipids
|x Metabolism
|
650 |
|
0 |
|a Antilipemic agents
|
650 |
|
2 |
|a Antilipemic Agents
|
650 |
|
2 |
|a Arteriosclerosis
|
650 |
|
2 |
|a Lipids
|x metabolism
|
650 |
|
2 |
|a Lipoproteins
|x metabolism
|
650 |
|
2 |
|a Metabolism
|x drug effects
|
650 |
0 |
7 |
|0 (DE-588)4035876-8
|0 (DE-627)106245368
|0 (DE-576)209015225
|a Lipidstoffwechselstörung
|2 gnd
|
650 |
0 |
7 |
|0 (DE-588)4059798-2
|0 (DE-627)106142216
|0 (DE-576)209132310
|a Therapie
|2 gnd
|
650 |
0 |
7 |
|0 (DE-588)4167796-1
|0 (DE-627)105422452
|0 (DE-576)209911247
|a Lipidsenker
|2 gnd
|
655 |
|
7 |
|a Konferenzschrift
|y 1986
|z Florenz
|0 (DE-588)1071861417
|0 (DE-627)826484824
|0 (DE-576)433375485
|2 gnd-content
|
689 |
0 |
0 |
|D s
|0 (DE-588)4035876-8
|0 (DE-627)106245368
|0 (DE-576)209015225
|a Lipidstoffwechselstörung
|2 gnd
|
689 |
0 |
1 |
|D s
|0 (DE-588)4059798-2
|0 (DE-627)106142216
|0 (DE-576)209132310
|a Therapie
|2 gnd
|
689 |
0 |
|
|5 DE-101
|
689 |
1 |
0 |
|D s
|0 (DE-588)4167796-1
|0 (DE-627)105422452
|0 (DE-576)209911247
|a Lipidsenker
|2 gnd
|
689 |
1 |
|
|5 DE-101
|
689 |
2 |
0 |
|D s
|0 (DE-588)4035876-8
|0 (DE-627)106245368
|0 (DE-576)209015225
|a Lipidstoffwechselstörung
|2 gnd
|
689 |
2 |
1 |
|D s
|0 (DE-588)4059798-2
|0 (DE-627)106142216
|0 (DE-576)209132310
|a Therapie
|2 gnd
|
689 |
2 |
|
|5 (DE-627)
|
689 |
3 |
0 |
|D s
|0 (DE-588)4167796-1
|0 (DE-627)105422452
|0 (DE-576)209911247
|a Lipidsenker
|2 gnd
|
689 |
3 |
|
|5 (DE-627)
|
700 |
1 |
|
|a Paoletti, Rodolfo
|e hrsg
|0 (DE-627)1232478962
|0 (DE-576)162478968
|4 edt
|
711 |
2 |
|
|a International Symposium on Drugs Affecting Lipid Metabolism
|n 9
|d 1986
|c Florenz
|0 (DE-588)2103937-9
|0 (DE-627)101013426
|0 (DE-576)193260883
|4 oth
|
711 |
2 |
9 |
|a Drugs Affecting Lipid Metabolism Meeting
|c Florenz
|d 1986.10.22-25
|
856 |
4 |
2 |
|u http://d-nb.info/880089067/04
|m B:DE-101
|q application/pdf
|v 20130501
|x Verlag
|3 Inhaltsverzeichnis
|
889 |
|
|
|w (DE-627)016152271
|
912 |
|
|
|a GBV_ILN_20
|
912 |
|
|
|a ISIL_DE-84
|
912 |
|
|
|a SYSFLAG_1
|
912 |
|
|
|a GBV_KXP
|
912 |
|
|
|a SSG-OLC-PHA
|
912 |
|
|
|a SSG-OPC-PHA
|
912 |
|
|
|a SSG-OPC-DE-84
|
912 |
|
|
|a GBV_ILN_22
|
912 |
|
|
|a ISIL_DE-18
|
912 |
|
|
|a GBV_ILN_22_i04813
|
912 |
|
|
|a GBV_ILN_31
|
912 |
|
|
|a ISIL_DE-27
|
912 |
|
|
|a GBV_ILN_40
|
912 |
|
|
|a ISIL_DE-7
|
912 |
|
|
|a GBV_ILN_65
|
912 |
|
|
|a ISIL_DE-3
|
912 |
|
|
|a GBV_ILN_65_a024
|
912 |
|
|
|a GBV_ILN_74
|
912 |
|
|
|a ISIL_DE-354
|
912 |
|
|
|a GBV_ILN_290
|
912 |
|
|
|a ISIL_DE-D267
|
912 |
|
|
|a GBV_ILN_2006
|
912 |
|
|
|a ISIL_DE-14
|
912 |
|
|
|a GBV_ILN_2008
|
912 |
|
|
|a ISIL_DE-24
|
912 |
|
|
|a GBV_ILN_2018
|
912 |
|
|
|a ISIL_DE-31
|
912 |
|
|
|a GBV_ILN_2021
|
912 |
|
|
|a ISIL_DE-289
|
935 |
|
|
|i Blocktest
|
936 |
b |
k |
|a 44.38
|j Pharmakologie
|0 (DE-627)106409743
|
951 |
|
|
|a BO
|
953 |
|
|
|2 045F
|a 616.3/997061
|
980 |
|
|
|2 20
|1 01
|x 0084
|b 017618150
|c 00
|f --%%--
|d 2667-5419
|e --%%--
|j --%%--
|y n
|z 01-01-71
|
980 |
|
|
|2 22
|1 01
|x 0018
|b 195920678
|c 00
|f 18/48
|d Fb 56
|e i
|j --%%--
|y zi04813
|z 02-09-96
|
980 |
|
|
|2 31
|1 01
|x 0027
|b 236176498
|c 00
|f Mag3
|d Mag3 A 1744
|e u
|j --%%--
|c 09
|f --%%--
|d 89 NA 380/1
|e --%%--
|j --%%--
|y r
|z 25-01-07
|
980 |
|
|
|2 40
|1 01
|x 7/11
|b 030128803
|c 00
|f BBM
|d XQU 85 d 87:1 = 88 A 11469
|e u
|j --%%--
|c 09
|f --%%--
|d 88 A 11469
|e --%%--
|j --%%--
|y xsn
|z 27-01-95
|
980 |
|
|
|2 65
|1 01
|x 3/150
|b 136635334
|c 00
|f Ha 150
|d Lip 35
|e u
|j --%%--
|y na024
|z 23-11-94
|
980 |
|
|
|2 74
|1 01
|x 0354
|b 030128811
|c 00
|f Magazin
|d MB 8487
|e u
|j --%%--
|y r
|z 24-01-13
|
980 |
|
|
|2 290
|1 01
|x 3290
|b 4296820702
|c 00
|f --%%--
|d DB 022
|e c
|j --%%--
|y k
|z 23-03-23
|
980 |
|
|
|2 2006
|1 01
|x DE-14
|b 3319998153
|c 00
|f --%%--
|d --%%--
|e --%%--
|j --%%--
|y l01
|z 29-03-11
|
980 |
|
|
|2 2008
|1 01
|x DE-24
|b 3319998226
|c 00
|f --%%--
|d 38a/1678
|e --%%--
|j --%%--
|k co
|y l01
|z 08-09-99
|
980 |
|
|
|2 2018
|1 01
|x DE-31
|b 3319998242
|c 00
|f --%%--
|d --%%--
|e --%%--
|j --%%--
|k 21.04.89/zw
|y l01
|z 21-04-89
|
980 |
|
|
|2 2021
|1 01
|x DE-289
|b 3319998331
|c 00
|f J
|d QU 85/1987 P
|e --%%--
|j --%%--
|y l01
|z 19-06-89
|
982 |
|
|
|2 74
|1 00
|x DE-354
|8 00
|a Hypolipidemic Agents
|
982 |
|
|
|2 74
|1 00
|x DE-354
|8 01
|a Arteriosclerosis-metabolism
|
982 |
|
|
|2 74
|1 00
|x DE-354
|8 02
|a Hyperlipidemias-drug therapy
|
982 |
|
|
|2 74
|1 00
|x DE-354
|8 03
|a Lipids-metabolism
|
982 |
|
|
|2 74
|1 00
|x DE-354
|8 04
|a Lipoproteins-metabolism
|
982 |
|
|
|2 74
|1 00
|x DE-354
|8 50
|a Congresses
|
982 |
|
|
|2 2021
|1 01
|x DE-289
|8 00
|s s
|0 (DE-627)1305828011
|a Lipids. Metabolism
|
982 |
|
|
|2 2021
|1 01
|x DE-289
|8 01
|s s
|0 (DE-627)1306751020
|a Antilipemic agents
|
983 |
|
|
|2 20
|1 00
|x DE-84
|8 00
|a 615.272.4
|
983 |
|
|
|2 22
|1 01
|x 0018
|8 00
|a H48 Fb
|
983 |
|
|
|2 31
|1 00
|x DE-27
|8 00
|a MED:PG
|
984 |
|
|
|2 20
|1 01
|x 0084
|a 84$026675419
|x 00
|
984 |
|
|
|2 22
|1 01
|x 0018
|a 104570744
|
984 |
|
|
|2 31
|1 01
|x 0027
|a 27$010838732
|
984 |
|
|
|2 40
|1 01
|x 7/11
|a 7$100802583
|x 00
|
984 |
|
|
|2 74
|1 01
|x 0354
|a 354$00153079
|
984 |
|
|
|2 290
|1 01
|x 3290
|a D267$1053248
|
985 |
|
|
|2 22
|1 01
|x 0018
|a h48.89.462
|
985 |
|
|
|2 65
|1 01
|x 3/150
|a 89/44
|
985 |
|
|
|2 74
|1 01
|x 0354
|a MB 8487
|
985 |
|
|
|2 290
|1 01
|x 3290
|a 04577
|